Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA.
Clin Colorectal Cancer. 2013 Jun;12(2):95-102. doi: 10.1016/j.clcc.2012.11.002. Epub 2013 Jan 12.
Self-administered questionnaires were completed by patients undergoing chemotherapy for stage III colon cancer (n=1095) and metastatic colorectal cancer (n=875). We describe the prevalence of a wide-range of health-related dietary patterns and lifestyle behaviors among colorectal cancer patients with stage III and metastatic disease and report notable similarities in these 2 cohorts.
Cancer patients often pursue lifestyle and dietary changes with the aim to improve outcomes. Using data from 2 large National Cancer Institute-sponsored clinical trials, we report on the dietary and lifestyle practices of patients receiving therapy for stage III colon or metastatic colorectal cancer.
Self-administered questionnaires were completed by patients undergoing chemotherapy for stage III colon cancer (n=1095) and metastatic colorectal cancer (n=875). Descriptive statistical analyses were performed to evaluate anthropometrics, diet, and lifestyle in each cohort.
Median body mass index was comparable for stage III and metastatic patients (27.3 vs. 26.5 kg/m2). Stage III patients reported a modestly higher median level of physical activity than metastatic patients (4.6 vs. 3.4 metabolic equivalent task-hours per week). Ten percent of stage III and 9% of metastatic patients reported ongoing cigarette use. Avoidance of alcohol was reported by 47% of stage III and 43% of metastatic patients. Dietary patterns for both groups were comparable with more than 80% of stage III and metastatic patients failing to meet the recommended daily intake of vegetables, fruits, and milk products. Usage of at least 2 multivitamins per week was reported by 49% of stage III and 40% of metastatic patients. Two percent of stage III and 5% of metastatic patients reported vitamin D supplement use.
We observed notable similarities in dietary and lifestyle behaviors between stage III colon and metastatic colorectal cancer patients actively receiving chemotherapy. Future research should aim to elucidate the effect of these behaviors on patient outcomes.
正在接受 III 期结肠癌（n=1095）和转移性结直肠癌（n=875）化疗的患者完成了自我管理的问卷。我们描述了广泛的与健康相关的饮食模式和生活方式行为在 III 期和转移性疾病的结直肠癌患者中的流行情况，并报告了这 2 个队列中这些行为的显著相似性。
癌症患者通常会采取生活方式和饮食方面的改变，以改善治疗效果。使用来自 2 个大型美国国立卫生研究院资助的临床试验的数据，我们报告了接受 III 期结肠癌或转移性结直肠癌治疗的患者的饮食和生活方式实践。
正在接受 III 期结肠癌（n=1095）和转移性结直肠癌（n=875）化疗的患者完成了自我管理的问卷。对每个队列的人体测量、饮食和生活方式进行描述性统计分析。
III 期和转移性患者的中位体重指数相当（27.3 与 26.5kg/m2）。III 期患者的体力活动中位数略高于转移性患者（4.6 与 3.4 代谢当量任务小时/周）。10%的 III 期和 9%的转移性患者报告持续吸烟。47%的 III 期和 43%的转移性患者避免饮酒。两组的饮食模式相似，超过 80%的 III 期和转移性患者未能达到推荐的蔬菜、水果和奶制品每日摄入量。49%的 III 期和 40%的转移性患者每周至少使用 2 种多种维生素。2%的 III 期和 5%的转移性患者报告使用维生素 D 补充剂。
我们观察到正在接受积极化疗的 III 期结肠癌和转移性结直肠癌患者在饮食和生活方式行为方面存在显著相似性。未来的研究应旨在阐明这些行为对患者结局的影响。
